LL-37
LL-37 (Human Cathelicidin Antimicrobial Peptide)
LL-37 is the only human member of the cathelicidin family of host defence peptides. Expressed by neutrophils, epithelial cells, and macrophages in response to infection or injury, it combines direct antimicrobial activity against bacteria, viruses, and fungi with potent immunomodulatory and wound-healing properties. Research interest spans chronic wound healing, respiratory infections, and cancer.
Mechanism of Action
LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechanism is effective against drug-resistant pathogens including MRSA.
Beyond antimicrobial activity, LL-37 activates multiple pattern recognition receptors (TLRs, P2X7), modulates macrophage polarisation toward M2 (healing) phenotype, promotes angiogenesis, and drives fibroblast and keratinocyte migration for wound closure.
LL-37 has been identified as a senolytic agent — research shows it selectively induces apoptosis in senescent (zombie) cells while sparing healthy cells, adding an anti-aging dimension to its biology.
Research Evidence
LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it a versatile research compound.
LL-37 Promotes Wound Healing via Epithelial and Vascular Effects
LL-37 stimulated keratinocyte migration, angiogenesis, and granulation tissue formation in excisional wound models, with topical application producing significantly faster wound closure versus controls.
Typical Research Protocol
Topical LL-37 is particularly studied for chronic non-healing wounds, psoriasis, and respiratory infections. Intranasal LL-37 has been studied as a COVID-19 mucosal immunity enhancer.
Safety Profile
Reported Side Effects
- Injection site pain (cytokine release)
- Mild erythema
- Headache (rare)
Contraindications
- Autoimmune conditions (immune stimulation)
- Active lupus (LL-37 is a lupus autoantigen in some patients)
- Pregnancy (no data)
Common Research Stacks
Frequently Asked Questions
Is LL-37 safe to use?
At physiological concentrations, LL-37 is well-tolerated and is a normal component of human immunity. At pharmacological doses in research, local reactions are the most common adverse effect. Importantly, LL-37 is an autoantigen in some lupus patients — where it complexes with DNA to trigger immune activation. Individuals with autoimmune conditions should use with caution.
How does LL-37 fight infections?
LL-37 kills bacteria by inserting its cationic amphipathic helical structure into negatively charged microbial membranes, causing irreversible membrane disruption. This mechanism is effective against drug-resistant bacteria (MRSA, Pseudomonas), viruses (including respiratory viruses by disrupting viral envelopes), and fungi. Unlike antibiotics, LL-37's membrane-disruption mechanism makes resistance development rare.
Can LL-37 help with chronic wounds?
Yes — LL-37 addresses multiple barriers to chronic wound healing simultaneously: antimicrobial protection (clears bacterial biofilm), immune modulation (polarises macrophages to healing M2 phenotype), angiogenesis (promotes new blood vessel growth to supply the wound), and direct cell migration stimulation for keratinocytes and fibroblasts. This multi-target profile makes it particularly valuable for biofilm-infected or non-healing wounds.
What is the relationship between LL-37 and vitamin D?
Vitamin D is a primary inducer of LL-37 expression. The CYP27B1 enzyme activated by vitamin D directly upregulates the cathelicidin/LL-37 gene in immune cells and epithelial cells. This pathway explains much of vitamin D's immune-protective effect against respiratory infections. Low vitamin D status correlates with reduced LL-37 production and increased infection susceptibility.
Is LL-37 being studied for cancer?
LL-37's biology in cancer is complex — it has pro-tumorigenic effects in some cancers (ovarian, breast) where it promotes tumour cell survival and angiogenesis, while showing anti-tumour effects in others (gastric cancer, melanoma). More recently, its senolytic activity (selective clearance of senescent cells, which can drive tumour microenvironment remodelling) has attracted interest. Cancer-related applications require careful context-specific evaluation.
Key Research References
- Zanetti M. (2004). Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol.
- Ramos R et al. (2011). Wound healing activity of human antimicrobial peptide LL-37. J Invest Dermatol.
Explore more Recovery research compounds
Browse Recovery →